Hyperion Therapeutics Announces Second Quarter 2013 Financial Results Teleconference and Webcast

Hyperion Therapeutics Announces Second Quarter 2013 Financial Results
Teleconference and Webcast

SOUTH SAN FRANCISCO, Calif., Aug. 8, 2013 (GLOBE NEWSWIRE) -- Hyperion
Therapeutics, Inc. (Nasdaq:HPTX) today announced that it will host a
teleconference and webcast with management to provide a general business
overview, as well as to discuss its second quarter 2013 financial results on
Wednesday, August 14, 2013 at 4:30 p.m. EDT (1:30 p.m. PDT.) Financial results
for the quarter ended June 30, 2013 will be released after market close on
August 14, 2013.

To access the live conference call, dial 877-847-7188 U.S. or 408-427-3787
International and use the conference ID# 21769835. Individuals may access the
live audio webcast at http://investors.hyperiontx.com/events.cfm. A replay of
the webcast will be available on the Company's website for 30 days following
the live event.

About Hyperion Therapeutics

Hyperion Therapeutics, Inc. is a commercial stage biopharmaceutical company
committed to developing and delivering life-changing treatments for orphan
diseases and hepatology. The company's first commercial product, Ravicti®
(glycerol phenylbutyrate) Oral Liquid, was approved in February 2013 and is
currently being marketed in the United States. The company also owns and
markets BUPHENYL® (sodium phenylbutyrate) Tablets and Powder worldwide. For
more information, please visit www.hyperiontx.com.

CONTACT: Sylvia Wheeler, Investor Relations
         (650) 794-7834
 
Press spacebar to pause and continue. Press esc to stop.